Richter Gedeon

Listed
Pharmaceutical manufacturing, research, and marketing in Hungary.

About Richter Gedeon

Richter Gedeon is a publicly listed company. Pharmaceutical manufacturing, research, and marketing in Hungary. Richter Gedeon has completed 2 acquisitions, including Finox Biotech and PregLem. Richter Gedeon offers products and services including Cariprazine and Biosimilars. Its focus areas include Pharmaceuticals, Drug Manufacturing, Research and Development and Biotechnology. Its legal entity is Richter Gedeon Nyrt.

Company details

Richter Gedeon is identified as a Hungarian-based multinational pharmaceutical company that engages in vertically integrated activities, including drug manufacturing, research and development, commerce, and marketing. Original research, womens health, and biotechnology are emphasized to deliver high-value products across various therapeutic areas. A workforce exceeding 1200 in RD positions it as a key player in Central and Eastern Europe, with a history dating back to 1901. Sustainability is addressed through long-term practices and social responsibility, ensuring innovative solutions for patients worldwide while maintaining ethical standards in operations. This approach supports its strategy to become a prominent midpharma entity in Europe.

Key Metrics
  • Annual Revenue
    $2.83 B (USD)
    8.33
    as on Dec 31, 2025
  • Net Profit
    $708.81 M (USD)
    -2.89
    as on Dec 31, 2025
  • EBITDA
    $1.1 B (USD)
    22.65
    as on Dec 31, 2025
  • Investments & Acquisitions

Products & Services of Richter Gedeon

Richter Gedeon offers a comprehensive portfolio of products and services, including Cariprazine and Biosimilars.

Cariprazine
Neuropsychiatry Drugs

This drug is used for treating psychiatric conditions and is developed as part of efforts in original research within the pharmaceutical sector.

Biosimilars
Biotechnology Products

Biosimilars are produced for treating conditions like osteoporosis and are manufactured through processes that emphasize innovation and therapeutic efficacy.

People of Richter Gedeon

37 people are tracked at Richter Gedeon (17 in leadership, 16 in board & advisors, 4 in team).

NameRoleGroup
Tibor Horváth
Commercial DirectorLeadership
Zsolt Safranka Dr.
Global Head Of Field Force OperationsLeadership
Gábor Orbán
CEOLeadership
Rita Utasi-Peszlen
Head Of Hr OperationsLeadership
Attila Szènàsi
Chief Operating OfficerLeadership
Viktor Dávid
Head Of Information Technology DepartmentLeadership
Gabor Szucs
Director Of Financial OperationsLeadership
Zoltán Hudivók Pharm.d.
Site Quality HeadLeadership
Katalin Losteiner-Fogassy
Head Of Biotechnology CDMO Project Management OfficeLeadership
Ádám Nagy
Head Of Project Methodology & Data ManagementLeadership
Kristóf Bozó Pharmd
Head Of Sterile Liquid Dosage Forms Packaging PlantLeadership
Matthieu Lehmann
Senior Director, Business Development & Market Insights Lead, FertilityLeadership
Janos Penzes
Global Head Of Digital Center Of ExcellenceLeadership
Mogyorós Attila
Head Of Portfolio Project Management OfficeLeadership
Emese Pál
Head Of GCP Quality Assurance DepartmentLeadership
Szilvia Módra Pharmd
Head Of DepartmentLeadership
Miklós Gondolovics
Head Of IT PMOLeadership
László Szabó
DirectorBoard & advisors
Lívia Pavlik
Board MemberBoard & advisors
Zoltán Matos
Board MemberBoard & advisors

17 more people are available in the full profile.

Premium access

Complete people profiles for Richter Gedeon

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Richter Gedeon

Richter Gedeon is a publicly listed company on the BET with ticker symbol RICHTER in Hungary, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date09 Nov 1994
  • Listed onBET: RICHTER
  • Listed entityChemical Works of Gedeon Richter Plc
  • Exchange sectorHealth technology
  • ISINHU0000123096
  • Share price12,610.00 HUF (+2.94% on the day) · 2026-10-14
  • Market capitalisation2,239,948,463,440.00 HUF
  • Price to earnings10.7
  • EPS (diluted, trailing year)1,181.37 HUF
  • Dividend yield5.35%
  • Volume (last session)36,440

Financials of Richter Gedeon

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025928.96B HUF232.34B HUF361.29B HUF
2024857.54B HUF239.24B HUF294.58B HUF
2023805.16B HUF158.85B HUF277.35B HUF
2022802.75B HUF169.08B HUF217.03B HUF
2021630.60B HUF139.63B HUF184.70B HUF
Premium access

Detailed financial statements for Richter Gedeon

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Richter Gedeon

Richter Gedeon has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Finox Biotech and PregLem.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Fertility products are developed by this Swiss biopharma firm.
finoxbiotech.comKirchdorf, Switzerland2007Jun 2016$193.8M
Innovative drugs for women's reproductive medicine are developed and commercialized.
preglem.comGeneva, Switzerland2006Oct 2010$155.6M
Premium access

Complete acquisition details for Richter Gedeon

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Richter Gedeon

3 dated milestones of Richter Gedeon across 22 years, from founding to its latest funding, stage changes and deals.

  1. IPO Lists on the stock exchange (IPO).
  2. Acquisition Acquires PregLem.
  3. Acquisition Acquires Finox Biotech.

Web traffic of Richter Gedeon

Websites that share an audience with Richter Gedeon (richter.hu).

Similar websites

Websites whose visitors overlap most with Richter Gedeon. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
serono.com
100%
View details
ferring.com
80%
39.6K#709,223View details
ucb.com
47%
146.5K#308,606View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Richter Gedeon

Premium access

Complete news archive for Richter Gedeon

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Richter Gedeon

Annual revenue of Richter Gedeon is $2.83B as on Dec 31, 2025.

Richter Gedeon is identified as a Hungarian-based multinational pharmaceutical company that engages in vertically integrated activities, including drug manufacturing, research and development, commerce, and marketing. Original research, womens health, and biotechnology are emphasized to deliver high-value products across various therapeutic areas. A workforce exceeding 1200 in RD positions it as a key player in Central and Eastern Europe, with a history dating back to 1901. Sustainability is addressed through long-term practices and social responsibility, ensuring innovative solutions for patients worldwide while maintaining ethical standards in operations. This approach supports its strategy to become a prominent midpharma entity in Europe.

Richter Gedeon offers Cariprazine and Biosimilars.

Yes, Richter Gedeon is publicly traded on BET under the ticker symbol RICHTER.

Richter Gedeon has made 2 acquisitions, including Finox Biotech, and PregLem.

Richter Gedeon operates through Richter Gedeon Nyrt.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available